Related Experiment Videos
Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout
Fu-Shun Yen1, Chih-Cheng Hsu2,3,4, Hsin-Lun Li5,6
1Dr. Yen's Clinic, Taoyuan City, Taiwan.
Insights
Urate-lowering therapy (ULT) significantly reduces the risk of stroke and all-cause mortality in gout patients. This finding suggests ULT may be beneficial for cardiovascular health in this population.
Area of Science:
- Cardiology
- Rheumatology
- Epidemiology
Background:
- Hyperuricemia is linked to cardiovascular (CV) diseases.
- Limited research exists on the impact of urate-lowering therapy (ULT) on CV disease incidence.
- Gout patients are a key population for studying these effects.
Purpose of the Study:
- To compare the risks of hospitalized coronary artery disease (CAD), stroke, heart failure (HF), and all-cause mortality.
- To evaluate these risks between ULT users and nonusers among patients diagnosed with gout.
Main Methods:
- Retrospective cohort study utilizing Taiwan's National Health Insurance Research Database (2000-2012).
- Included 5218 patients with gout, comparing ULT users with matched nonusers.
- Analyzed incidence rates (IRs) and adjusted hazard ratios (aHR) for key CV events and mortality.
Main Results:
- ULT users had significantly lower adjusted hazard ratios for hospitalized stroke (aHR: 0.52) and all-cause mortality (aHR: 0.6) compared to nonusers.
- Incidence rates of hospitalized stroke were 0.6 per 100 person-years for ULT users versus 1.0 for nonusers.
- Uricosuric agents and xanthine oxidase inhibitors showed significant associations with reduced stroke and mortality risks, respectively, with a dose-response for uricosurics on stroke risk.
Conclusions:
- ULT use is associated with reduced risks of hospitalized stroke and all-cause mortality in patients with gout.
- These findings suggest that ULT can be a strategy to mitigate cardiovascular and mortality risks in gout patients.
- Further research into specific ULT agents and their CV benefits is warranted.
Objectives:
Although studies have demonstrated the association of hyperuricemia with cardiovascular (CV) diseases, few have explored the effect of urate-lowering therapy (ULT) on the incidence of CV diseases. Therefore, we compared the risks of hospitalized coronary artery disease (CAD), stroke, heart failure (HF), and all-cause mortality between ULT users and nonusers among patients with gout.
Methods:
We performed this retrospective cohort study using Taiwan's population-based National Health Insurance Research Database. In total, 5218 patients with gout were included from 2000 to 2012. We compared the incidence rates (IRs) of hospitalized CAD, stroke, HF, and all-cause mortality between ULT users and matched nonusers.
Results:
The IRs of hospitalized stroke were 0.6 and 1.0 per 100 person-years for ULT users and nonusers, respectively, after adjusting for age, sex, residence, comorbidities, and medications. ULT users showed lower adjusted hazard ratios (aHR) for hospitalized stroke (aHR: 0.52, p < 0.001) and all-cause mortality (aHR: 0.6, p = 0.02) than nonusers. Subgroup analyses revealed that uricosuric agents and xanthine oxidase inhibitors were significantly associated with lower risks of hospitalized stroke and all-cause mortality, respectively. The effect of uricosuric agents on the decrease in hospitalized stroke risk indicated a dose-response relationship.
Conclusions:
Our study showed lower risks of hospitalized stroke and all-cause mortality in ULT users than in nonusers among patients with gout. Therefore, patients with gout may receive ULT to mitigate the risks of hospitalized stroke and mortality.
Related Concept Videos
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Peripheral Artery Disease III: Interprofessional Care
Atherosclerosis III: Management
Antihypertensive Drugs: Action of Diuretics
Urinary Tract Calculi III: Medical Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System